about
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsEvaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsDiscontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic reviewA randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART.Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study.Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions.Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infectionRemodeling of the plasma membrane in preparation for sperm-egg recognition: roles of acrosomal proteins.Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structuresThe Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Interactions between protease inhibitors and acid-reducing agents: a systematic review.Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.Expression of γ-chain cytokine receptors on CD8+ T cells in HIV infection with a focus on IL-7Rα (CD127).Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity?Circulating endothelial progenitor cells in HIV infection: a systematic review.A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells.HIV infection of thymocytes inhibits IL-7 activity without altering CD127 expression.Type I interferon responses are impaired in latently HIV infected cells.Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception.HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine.PI3K/Akt regulates survival during differentiation of human macrophages by maintaining NF-κB-dependent expression of antiapoptotic Bcl-xL.Complexed soluble IL-7 receptor α and IL-7 increase IL-7-mediated proliferation and viability of CD8⁺ T-cells in vitro.Cardiovascular complications of Salmonella enteritidis infection.Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication.Disparate regulation of LPS-induced MAPK signaling and IL-12p40 expression between different myeloid cell types with and without HIV infection.HIV and HIV-Tat inhibit LPS-induced IL-27 production in human macrophages by distinct intracellular signaling pathways.Virologic and immunologic activity of PegIntron in HIV disease.An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy.Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.Proteomic Characterization of Pig Sperm Anterior Head Plasma Membrane Reveals Roles of Acrosomal Proteins in ZP3 Binding.The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada.CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection.Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome.Acute phase responses and cytokine secretion in chronic fatigue syndrome.
P50
Q26768591-417F5C6B-18D5-4A41-A0B2-6509F6B34E60Q26777442-46213FE2-8A6A-4242-B31F-28E7A8C9AE2FQ26829541-C16D559D-666B-4F43-982B-894CA050DE8FQ30230364-80F6581D-D590-43C6-827E-29267B0D1E8BQ33494834-2DC6ACED-290D-460E-A288-F49B982B511DQ33517626-9025900F-0B7C-49A3-A5B4-B57123FA3F02Q33760825-1F3177DB-072B-4EEF-A6A7-81E0B4C07FDAQ34249596-3B2C02A0-7234-4B26-837A-2C29D846EF75Q35028707-D03F82E1-466B-4E99-9879-54652E03551AQ35146353-DE28EEF1-6DA0-45BE-90BA-62BAD1A9EDD2Q35819830-C47E810C-F97E-425D-AAFC-CEC46A0EAAE7Q36037105-79D082A8-CFA9-4651-9441-27974C1A3307Q36080407-FB08956C-8940-43EE-9AF7-E15CF77B85A7Q36296993-58F18408-2174-4340-980C-2B2CD3F95E11Q36813547-739F195A-9A49-477D-AEF3-2441531D5992Q36895942-C6D15E4F-E9D0-4206-AEC8-F0CD36DA7C3CQ37405336-8CED80D3-9825-490D-97C2-1F9FE3B46998Q37921607-E1EF26F0-392B-4AE0-9571-797ED9B7A30AQ38038756-6D8AD004-4031-4625-A06A-45A82CAB5045Q38080315-5C9B47DF-2EC7-42FE-9432-E54FCE0F77D3Q38169257-42C7FF37-DB38-4E88-9B77-802A1C7A8490Q38310502-3C51F05E-A3AA-4021-A4B5-B28419936BCCQ38591354-81083CAB-D27E-4922-A05A-ACDD5A872A09Q38747126-8DB69758-5A13-4A49-9FC0-DA96B179F973Q38796194-44EAE08A-CD7C-4B34-8901-1122D60AC570Q38856258-13E9DA61-37C5-43D7-91D0-B08A6884CDF4Q38956169-8BE0328C-FB47-40DD-A4C2-84AE025FF812Q39055845-1ABF47CE-0B9A-475D-9EE5-15CA96C3F3ADQ39066794-49826F0D-0F0B-49E5-B559-BBF43C02641CQ39271137-28111F6F-6CF2-47F1-949D-0E18EF7097C8Q39745489-9D92EA03-E74E-4886-B741-B6894D0A5CF4Q40139039-23659D84-BBDD-4703-9EF8-BAC62696B0A3Q40374514-33077294-DB60-44E7-A132-1CB5C6AC99FAQ40607256-670A617B-DC09-4762-A030-45421A000F89Q41921243-58A4FE12-5585-4FA4-8578-B96ADF9D2FD9Q42203769-22E7CDD4-2D1D-45C0-B213-C1BD33300DD4Q42241438-D935A0FA-A2D4-414E-956A-A4E17FD71762Q42422809-B0FCC6DF-1983-4102-B81D-465CDE7175AEQ42460095-3ED0E270-ABC3-4C6A-B1FA-F4F96BB0F326Q42482281-66876FA1-EFE8-4CBF-A39F-47C08FBA2290
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-3102-4462
@en
name
Jonathan B Angel
@ast
Jonathan B Angel
@en
Jonathan B Angel
@es
Jonathan B Angel
@nl
type
label
Jonathan B Angel
@ast
Jonathan B Angel
@en
Jonathan B Angel
@es
Jonathan B Angel
@nl
prefLabel
Jonathan B Angel
@ast
Jonathan B Angel
@en
Jonathan B Angel
@es
Jonathan B Angel
@nl
P106
P1153
7101775728
P21
P31
P496
0000-0003-3102-4462